AbbVie Inc. ( NYSE:ABBV ) struggles with declining sales volumes of its blockbuster arthritis drug, Humira. Despite a positive outlook for its newer immunology treatments, Skyrizi and Rinvoq, concerns over the impact of biosimilar competition and shifting patient preferences have cast a shadow over the pharmaceutical giant's performance, leading to a dip in its...
Pharmaceutical giant AbbVie Inc. is considering enhancing its neurobiological portfolio as it finalises the acquisition of neurobiotech firm Cerevel Therapeutics. Initially announced in December 2023 for 8.7 billion USD, the acquisition was primarily focused on Cerevel's experimental schizophrenia drug, Emraclidine. This drug represents a new class of...
Entry Price (173.97) : Chosen based on Fibonacci retracement levels, suggesting a potential point to buy or enter the stock, expecting the price to increase from this level. Take Profit (179.97) : Set near a Fibonacci extension or resistance level, indicating a target price to sell and secure profits before the stock might pull back. Stop Loss (171.97) :...
If you haven`t bought the dip on ABBV: Then analyzing the options chain and the chart patterns of ABBV AbbVie prior to the earnings report this week, I would consider purchasing the 160usd strike price Calls with an expiration date of 2024-3-15, for a premium of approximately $7.55. If these options prove to be profitable prior to the earnings release, I would...
SPDR Select Sector Fund – Healthcare Index AMEX:XLV The chart speaks for itself, we have our breakout levels and our break down levels. We enter on a breakout and set a stop 5% under that support and we exit and or short if we fall under the two underside support levels. Below I outline some reasons why the healthcare sector is worth paying attention too....
ABBV is on a bearish 1D technical outlook (RSI = 39.987, MACD = -1.990, ADX = 42.078) but is quite possibly forming a short term bottom as the 1D RSI rebounded from an oversold level (under 30.00), while the MACD is close to forming a Bullish Cross. Every time those two conditions were fulfilled simultaneously inside the 1 year Channel Down, the price was a buy....
If you haven`t bought the dip on ABBV here: Then analyzing the options chain and the chart patterns of ABBV AbbVie prior to the earnings report this week, I would consider purchasing the 147usd strike price Calls with an expiration date of 2023-11-17, for a premium of approximately $3.30. If these options prove to be profitable prior to the earnings release, I...
ABBV is taking a nap Above 153 we can see a bullish sentiment Below 146 we can see a bearish trend As I can see, there are more probability of going up But, what do you think?
Analyzing the options chain and the chart patterns of ABBV AbbVie prior to the earnings report this week, I would consider purchasing the 150usd strike price Calls with an expiration date of 2023-9-15, for a premium of approximately $2.46. If these options prove to be profitable prior to the earnings release, I would sell at least half of them. Looking forward to...
AbbVie Inc. (ABBV) is having the strongest 1D candle since October 13 2022, hitting the 1D MA200 (orange trend-line) for the first time in almost three months. The long-term pattern is a Channel Down and this one is the bullish leg to a new Lower High. The 1D RSI has breached into overbought (70.00>) territory so any pull-back is a buy, even on the current...
As it shown on the chart NYSE:ABBV it is a good zone to open a new position because it is trading near by a daily support My Stop Loss 4 Hours close lower than the support zone 133$ What do you think about ABBV ?
This idea is based on Wyckoff's method for determining price objectives using the Point & Figure count of distribution ranges. We can a distribution ranges following schematic 2 for Wyckoff's distribution. If we take count the ranges separately, this yields a potential reversal zone between 118.50 and 94.50 dollar per share. Personally I am intend to buy if...
Analyzing the options chain of ABBV AbbVie prior to the earnings report this week, I would consider purchasing the 175usd strike price Calls with an expiration date of 2024-1-19 for a premium of approximately $6.90. If these options prove to be profitable prior to the earnings release, I would sell at least half of them. I am interested to hear your thoughts on...
Based on weekly timeframe, ABBV at resistance of trend line.
ABBV has been in a down trend since the start of the year. With a break of the bear flag there is now only the long term trendline to save it.
AbbVie Inc. (ABBV) opened today much higher than the 1D MA200 (orange trend-line), which is a strong enough buy signal on its own. Coupled however with the fact that the rebound was achieved on the Higher Lows trend-line that started way back on the COVID (March 23 2020) market bottom, it makes it an even stronger one. In fact on a 2-3 month basis, this is the...
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behcet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in...
Hey traders, My weekly trade idea. The daily price is forming a textbook Cup&Handle formation. After the consolidation in the handle phase, the price is ready to go higher. The momentum will push the price and in my opinion, it is headed to test the all-time high in the 180$ area. The Relative Strength Index broke above its trend line and is moving upward to...